Faeth Therapeutics, Inc.
FTHHealthcareNASDAQBiotechnology
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. Valued at $597.8M, FTH is a small-cap name in its sector. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Market Cap
$597.8M
Beta
-0.23
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-144.75
EPS (Fwd)
—
ROE
—
ROA
-95.2%
Cash
$202.8M
Total Debt
$1.0M
Free CF
-$92.2M
52W Change
173.8%
Annual Financials
Cash vs Debt
Faeth Therapeutics, Inc. holds $202.8M in cash against $1.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$92.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
The relatively low beta of -0.23 suggests FTH is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Faeth Therapeutics, Inc. and its sector.